Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

Bristol-Myers Squibb (BMS) building

BMS halts hep C candidate development after patient death

Promises to share drug data to assist other pharma companies’ patient safety measures

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

Amgen-Takeda’s ganitumab fails in pancreatic cancer study

Interim analysis shows no improvement in overall survival

Novartis day

Novartis signs cancer immunotherapy deal with Penn

R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies

Bristol-Myers Squibb (BMS) building

BMS halts trial of hepatitis C drug on safety issues

At least one person in study thought to have developed congestive heart failure

- PMLiVE

Interview: Joseph Jimenez, Novartis

Novartis' CEO tells Linda Banks how investing in innovation and parallel development is helping to keep the company at the forefront

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links